Join Optimum Strategic Communications on Thursday, 10th October 2024 for our Annual Investor Healthcare Conference.
Now in its 16th year, the conference is firmly established as a major thought leadership event in Europe, bringing together the top executives and visionaries from the healthcare industry and investment community to discuss and debate the trends set to reshape the industry far into the future.
We look forward to meeting you again this autumn, at the The Kings Fund, London.
Reviews from our past speakers on what makes Optimum's Healthcare Investor Conference unique.
Leading speakers from the healthcare and investment communities providing insights on the latest trends and impacts on the industry.
A selection of some of our brilliant panellists from previous years.
Professor Chris Whitty UK Government
Linden Thomson AXA Investment Managers
Annalisa Jenkins Genomics England
Kasim Kutay Novo Holdings
Professor Tony Young OBE NHS England
Edwin Moses NED Various
Maina Bhaman Sofinnova Partners
Deborah Harland SR One
Oliver Maier Bayer
Kate Bingham UK Vaccine Taskforce, SV Health Investors
Professor James Logan The London School of Hygience and Tropical Medicine
Rajeev Venkayya Takeda Pharmaceuticals
Sean Marett BioNTech.jpg)
Peter Stein Norgine Group
Mike Ward Decision Resources Group, part of Clarivate
Elisa Petris Syncona.jpg)
Guillaume Vignon BeiGene
Philippe Lopes-Fernandes Ipsen
Kevin Mannix Teva Pharmaceutical Industries Ltd
Stavros Mercouris KKR
Isabella Eichler Altor Private Equity
Werner Lanthaler Evotec
Anne Marden JP Morgan Asset Management
Jan van de Winkel Genmab
Antoine Papiernik Sofinnova Partners
Martin Murphy Syncona
Paul Major Bellevue Asset Management
Roel Bulthuis Inkef Capital
David Pinniger Polar Capital
Vicky Darbyshire JP Morgan Asset Management
George Freeman Government adviser on Life Sciences
Gavin MacGregor HBM Partners
Andrew Holder Mole Valley Asset Management
Richard Girling Centreview Partners
Justin Stebbing Imperial College London
Lisa Urquhart Vantage
Thomas Burt Sofinnova
Harry Destecroix Unit DX
Ilan Chaitowitz Nomura Asset Management
Dale Raine Lazard
Jonathan Tobin Arix Bioscience
Soren Moller Novo Holdings
Jasper Bos M Ventures
Marc Booty Pictet Asset Management
Ian Nicholson F2G
Anker Lundemose Mission Therapeutics
Sam Fazeli Bloomberg Intelligence
Professor Sir Michael Rawlins NICE
Andy Richards CBE NED Various
Rice Powell Fresenius Medical Care
John Dawson Oxford Biomedica
Lisa Anson Redx Pharma
Amber Tong Endpoints News
Ulrica Slåne Bjerke Arctic Asset Management
Joe Anderson Sofinnova Partners
Naveed Siddiqi Novo Holdings
Stephen Hansen BioCenturyOptimum Strategic Communications
Optimum Strategic Communications is an international healthcare communications firm which specialises in strategic investor relations, corporate and financial communications. Our senior healthcare specialists, based in London, Amsterdam, Stockholm, Zurich, and New York, are experienced and trusted advisors to some of the world’s most exciting public and private companies, both large and small, across healthcare, life sciences and industrial biotechnology.
Over the last 20 years we have worked with over 300 healthcare companies, advising them on financial communications and investor relations, including major corporate activities such as fundraising, IPOs, and M&A, as well as corporate reputation and crisis scenarios.
We have an exceptional network of contacts across the international investment community in Europe and the US; contacts we have built and maintained over the last three decades. Our team includes ex-fund managers and analysts, scientists, as well as financial and corporate communications specialists.
For more information, please visit www.optimumcomms.com.
Chair: Nick Bastin, Managing Director, Optimum Strategic Communications
With the global life sciences market roaring back to life after a flat few years, join our panel of experts from across the market to discover what it hot and what is not as investors look to put their capital to work.
Chair: Catherine Pickering, Co-founder & Chief Executive Officer, iOnctura
Join Dr Daniel Mahony of Novo Holdings, Growth Investments, as he talks to Nerida Scott, the Head of Johnson & Johnson Innovation EMEA, about her career and her approach identifying and accelerating science and technology across consumer health, medical devices and pharmaceuticals.
Chair: Dr Daniel Mahony, Senior partner, Novo Holdings, Growth Investments
The Hevolution Foundation is the revolutionary new sovereign wealth fund from the Kingdom of Saudi Arabia which is looking to transform our quality of life by investing at scale in extending our “healthspan” - the period of time we live healthy lives. With significant pools of capital to put to work, hear from Dr Khan on the vision for the fund and the investments the Foundation is looking to make.
Clive Cookson, Senior Science Writer, Financial Times
While America is often seen as dominating the life sciences landscape, European champions can succeed and flourish in this competitive environment. Join our highly experienced panel and hear how they have achieved success in building highly innovative businesses.
Chair: Simon Amies, Partner, Cooley
We look forward to welcoming you to our conference.
The Kings Fund, London
Looking for a place to stay? We have special group rates at two nearby hotels - The Treehouse & The Marylebone Hotel.Email us for more information at irconference@optimumcomms.com.We think so too, so why not click the Register button below fill out your details and get ready for our 16th Annual Healthcare Investor Conference